Private Advisor Group LLC lowered its position in C.R. Bard, Inc. (NYSE:BCR) by 86.4% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,758 shares of the medical instruments supplier’s stock after selling 17,517 shares during the quarter. Private Advisor Group LLC’s holdings in C.R. Bard were worth $877,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently made changes to their positions in BCR. SRS Capital Advisors Inc. increased its stake in shares of C.R. Bard by 0.7% during the first quarter. SRS Capital Advisors Inc. now owns 598 shares of the medical instruments supplier’s stock valued at $148,000 after acquiring an additional 4 shares during the period. Alps Advisors Inc. increased its stake in shares of C.R. Bard by 0.3% during the second quarter. Alps Advisors Inc. now owns 1,921 shares of the medical instruments supplier’s stock valued at $607,000 after acquiring an additional 5 shares during the period. Parallel Advisors LLC increased its stake in shares of C.R. Bard by 2.8% during the second quarter. Parallel Advisors LLC now owns 513 shares of the medical instruments supplier’s stock valued at $164,000 after acquiring an additional 14 shares during the period. Blair William & Co. IL increased its stake in shares of C.R. Bard by 0.9% during the first quarter. Blair William & Co. IL now owns 3,492 shares of the medical instruments supplier’s stock valued at $865,000 after acquiring an additional 30 shares during the period. Finally, First Merchants Corp increased its stake in shares of C.R. Bard by 0.6% during the second quarter. First Merchants Corp now owns 5,135 shares of the medical instruments supplier’s stock valued at $1,623,000 after acquiring an additional 32 shares during the period. Institutional investors own 79.34% of the company’s stock.

In related news, insider John P. Groetelaars sold 23,687 shares of the business’s stock in a transaction that occurred on Thursday, August 10th. The shares were sold at an average price of $318.73, for a total transaction of $7,549,757.51. Following the completion of the sale, the insider now directly owns 31,445 shares of the company’s stock, valued at $10,022,464.85. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 0.80% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/09/12/private-advisor-group-llc-has-877000-holdings-in-c-r-bard-inc-bcr.html.

Shares of C.R. Bard, Inc. (BCR) opened at 323.73 on Tuesday. The company has a market capitalization of $23.53 billion, a PE ratio of 42.50 and a beta of 0.60. The company’s 50-day moving average is $320.16 and its 200-day moving average is $295.78. C.R. Bard, Inc. has a one year low of $203.63 and a one year high of $324.58.

C.R. Bard (NYSE:BCR) last posted its quarterly earnings results on Thursday, July 27th. The medical instruments supplier reported $2.92 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.84 by $0.08. The business had revenue of $979.70 million during the quarter, compared to the consensus estimate of $976.53 million. C.R. Bard had a net margin of 14.99% and a return on equity of 48.70%. C.R. Bard’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.54 earnings per share. Equities analysts predict that C.R. Bard, Inc. will post $11.84 earnings per share for the current year.

BCR has been the topic of a number of research analyst reports. Zacks Investment Research upgraded shares of C.R. Bard from a “hold” rating to a “buy” rating and set a $351.00 price objective on the stock in a research note on Tuesday, June 6th. BidaskClub upgraded shares of C.R. Bard from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 8th. BMO Capital Markets reiterated a “hold” rating and set a $317.00 price objective on shares of C.R. Bard in a research note on Tuesday, July 11th. Finally, Jefferies Group LLC reiterated a “hold” rating on shares of C.R. Bard in a research note on Thursday, August 3rd. One analyst has rated the stock with a sell rating, eight have issued a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Hold” and an average price target of $285.67.

C.R. Bard Company Profile

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Want to see what other hedge funds are holding BCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C.R. Bard, Inc. (NYSE:BCR).

Institutional Ownership by Quarter for C.R. Bard (NYSE:BCR)

Receive News & Stock Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related stocks with our FREE daily email newsletter.